Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement.
Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2005 May; 3(5):962-8.
View in:
PubMed
subject areas
Aged
Aged
Arthroplasty, Replacement, Hip
Arthroplasty, Replacement, Hip
Bandages
Bandages
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Enzyme-Linked Immunosorbent Assay
Enzyme-Linked Immunosorbent Assay
Female
Female
Fibrinolytic Agents
Fibrinolytic Agents
Hemoglobins
Hemoglobins
Hemorrhage
Hemorrhage
Humans
Humans
Male
Male
Middle Aged
Middle Aged
Phlebography
Phlebography
Postoperative Complications
Postoperative Complications
Protein C
Protein C
Recombinant Proteins
Recombinant Proteins
Thromboembolism
Thromboembolism
Thrombomodulin
Thrombomodulin
Time Factors
Time Factors
Treatment Outcome
Treatment Outcome
Venous Thrombosis
Venous Thrombosis
authors with profiles
Philip Cinnamon Comp